Boehringer Ingelheim Pharma GmbH & Co. KG

Industry / private company

Location: Ingelheim am Rhein, Germany (DE) DE

ISNI: 0000000121717500


Show on Map:


Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year




A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions (2023) Geßner A, Müller F, Wenisch P, Heinrich M, König J, Stopfer P, Fromm M Journal article Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, with Cytochrome P450 and P-Glycoprotein Substrates: Findings from in Vitro Analyses and an Open-Label, Single-Sequence Phase i Study (2023) Desch M, Schlecker C, Hohl K, Liesenfeld KH, Chan T, Müller F, Wunderlich G, et al. Journal article Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. (2023) Lescoat A, Huscher D, Schoof N, Airo P, De Vries-Bouwstra J, Riemekasten G, Hachulla E, et al. Journal article Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis (2023) Koop K, Enderle K, Hillmann M, Ruspeckhofer L, Vieth M, Sturm G, Trajanoski Z, et al. Journal article N1-Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid (2023) Müller F, Hohl K, Keller S, Schmidt-Gerets S, Deutsch B, Schuler-Metz A, Fromm M, et al. Journal article Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects (2022) Maher TM, Bourdin A, Volkmann ER, Vettori S, Distler J, Alves M, Stock C, Distler O Journal article Alveolar macrophages in early stage COPD show functional deviations with properties of impaired immune activation (2022) Bassler K, Fujii W, Kapellos TS, Dudkin E, Reusch N, Horne A, Reiz B, et al. Journal article "EFFECTIVE LUNG AGE" IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL (2022) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) (2022) Bernabei R, Landi F, Calvani R, Cesari M, Del Signore S, Anker SD, Bejuit R, et al. Journal article Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment (2022) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Journal article